Psychedelics Road Ahead: Are We Ready?
Psychedelics are classed as a schedule I substance under the Controlled Substances Act of 1970 because of the potential for mind-changing effects. In vulnerable people, unsupervised use has the potential to lead to suicide. However, the management of end-of-life anxiety, severe resistant depression,...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Jaypee Brothers Medical Publisher
2022-03-01
|
| Series: | Indian Journal of Private Psychiatry |
| Subjects: | |
| Online Access: | https://www.ijiapp.com/doi/IJPP/pdf/10.5005/jp-journals-10067-0113 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849700351764070400 |
|---|---|
| author | Mahesh R Gowda |
| author_facet | Mahesh R Gowda |
| author_sort | Mahesh R Gowda |
| collection | DOAJ |
| description | Psychedelics are classed as a schedule I substance under the Controlled Substances Act of 1970 because of the potential for mind-changing effects. In vulnerable people, unsupervised use has the potential to lead to suicide. However, the management of end-of-life anxiety, severe resistant depression, resistant obsessive–compulsive disorder, and substance abuse is met with a high failure rate. The preliminary study on psychedelics has yielded promising results, prompting the Food and Drug Administration (FDA) to classify them as a breakthrough medicine. More phase 3 research, funded by pharmaceutical company, are in the works. Similar studies should be funded by national institutes and government bodies to ensure unbiased results, as the findings of such studies may need legislative changes. |
| format | Article |
| id | doaj-art-b177db36f53f4567a7b6b336ac0482f2 |
| institution | DOAJ |
| issn | 2319-5363 2583-4010 |
| language | English |
| publishDate | 2022-03-01 |
| publisher | Jaypee Brothers Medical Publisher |
| record_format | Article |
| series | Indian Journal of Private Psychiatry |
| spelling | doaj-art-b177db36f53f4567a7b6b336ac0482f22025-08-20T03:18:18ZengJaypee Brothers Medical PublisherIndian Journal of Private Psychiatry2319-53632583-40102022-03-011611210.5005/jp-journals-10067-01131Psychedelics Road Ahead: Are We Ready?Mahesh R Gowda0Mahesh R Gowda, Spandana Nursing Home, Bengaluru, Karnataka, India, Phone: +91 9035560000Psychedelics are classed as a schedule I substance under the Controlled Substances Act of 1970 because of the potential for mind-changing effects. In vulnerable people, unsupervised use has the potential to lead to suicide. However, the management of end-of-life anxiety, severe resistant depression, resistant obsessive–compulsive disorder, and substance abuse is met with a high failure rate. The preliminary study on psychedelics has yielded promising results, prompting the Food and Drug Administration (FDA) to classify them as a breakthrough medicine. More phase 3 research, funded by pharmaceutical company, are in the works. Similar studies should be funded by national institutes and government bodies to ensure unbiased results, as the findings of such studies may need legislative changes.https://www.ijiapp.com/doi/IJPP/pdf/10.5005/jp-journals-10067-0113lsdmdmapsilocybinpsychedelicspsychoactive drug |
| spellingShingle | Mahesh R Gowda Psychedelics Road Ahead: Are We Ready? Indian Journal of Private Psychiatry lsd mdma psilocybin psychedelics psychoactive drug |
| title | Psychedelics Road Ahead: Are We Ready? |
| title_full | Psychedelics Road Ahead: Are We Ready? |
| title_fullStr | Psychedelics Road Ahead: Are We Ready? |
| title_full_unstemmed | Psychedelics Road Ahead: Are We Ready? |
| title_short | Psychedelics Road Ahead: Are We Ready? |
| title_sort | psychedelics road ahead are we ready |
| topic | lsd mdma psilocybin psychedelics psychoactive drug |
| url | https://www.ijiapp.com/doi/IJPP/pdf/10.5005/jp-journals-10067-0113 |
| work_keys_str_mv | AT maheshrgowda psychedelicsroadaheadareweready |